Abstract | BACKGROUND: Despite numerous therapeutic modalities reported in the literature, treatment of common warts remains a continuing challenge and there is no universal consensus about optimal treatment. Recently, intralesional immunotherapy by different antigens has proved efficacy in the treatment of different types of warts. OBJECTIVE: METHODS: The study included 135 patients with single or multiple recalcitrant or non-recalcitrant common warts. They were randomly assigned to two groups; the first group (85 patients) received intralesional MMR vaccine, and the second group (50 patients) received intralesional saline as a control group. Both treatments were injected into single lesions or largest wart in case of multiple lesions at 2-week intervals until complete clearance or for a maximum of five treatments. Follow-up was made every 2 months for 6 months to detect any recurrence. RESULTS: A highly significant difference was found between the therapeutic response of common warts to MMR vaccine and saline control group (P < 0.001). In the MMR group, complete response was achieved in 80% and 84.6% of patients presenting with recalcitrant and multiple warts respectively. No recurrence was observed in the MMR group and side effects included pain during injection and flu-like symptoms. CONCLUSIONS: Intralesional immunotherapy by MMR vaccine is a promising effective and safe treatment modality for common warts, particularly the multiple ones.
|
Authors | A Nofal, E Nofal |
Journal | Journal of the European Academy of Dermatology and Venereology : JEADV
(J Eur Acad Dermatol Venereol)
Vol. 24
Issue 10
Pg. 1166-70
(Oct 2010)
ISSN: 1468-3083 [Electronic] England |
PMID | 20202055
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | © 2010 The Authors. Journal of the European Academy of Dermatology and Venereology © 2010 European Academy of Dermatology and Venereology. |
Chemical References |
- Measles-Mumps-Rubella Vaccine
|
Topics |
- Adolescent
- Adult
- Female
- Follow-Up Studies
- Humans
- Immunotherapy
- Male
- Measles-Mumps-Rubella Vaccine
(adverse effects, therapeutic use)
- Middle Aged
- Recurrence
- Treatment Outcome
- Warts
(therapy)
- Young Adult
|